Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ARWR

Arrowhead Pharmaceuticals Inc

Dec 26 • 01:07PM ET

19.59

Dollar change -0.04
Percentage change -0.21	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY IONS SRPT NBIX DTIL VRTX RGNX CRSP EDIT NTLA

| Held by: VTI IJH VB IWM VXF VBK XBI IWO MDY IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.00	Insider Own	6.64%	Shs Outstand	124.38M	Perf Week	-3.79%
Market Cap	2.44B	Forward P/E	-	EPS next Y	-3.33	Insider Trans	-0.85%	Shs Float	116.00M	Perf Month	4.25%
Income	-599.49M	PEG	-	EPS next Q	-0.41	Inst Own	76.60%	Short Float	8.43%	Perf Quarter	-0.16%
Sales	3.55M	P/S	686.63	EPS this Y	49.93%	Inst Trans	-0.53%	Short Ratio	6.87	Perf Half Y	-23.75%
Book/sh	1.49	P/B	13.14	EPS next Y	-33.16%	ROA	-62.93%	Short Interest	9.78M	Perf Year	-36.59%
Cash/sh	5.47	P/C	3.58	EPS next 5Y	7.33%	ROE	-262.48%	52W Range	17.05 - 39.83	Perf YTD	-35.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-58.15%	52W High	-50.82%	Beta	0.94
Dividend TTM	-	Quick Ratio	6.74	Sales past 5Y	-2.87%	Gross Margin	-423.66%	52W Low	14.89%	ATR (14)	1.24
Dividend Ex-Date	-	Current Ratio	6.74	EPS Y/Y TTM	-160.68%	Oper. Margin	-16927.06%	RSI (14)	40.35	Volatility	5.90% 6.99%
Employees	609	Debt/Eq	4.59	Sales Y/Y TTM	-98.52%	Profit Margin	-16882.37%	Recom	1.71	Target Price	43.42
Option/Short	Yes / Yes	LT Debt/Eq	4.56	EPS Q/Q	-34.15%	Payout	-	Rel Volume	0.34	Prev Close	19.63
Sales Surprise	-100.00%	EPS Surprise	-21.39%	Sales Q/Q	-100.00%	Earnings	Nov 26 AMC	Avg Volume	1.42M	Price	19.59
SMA20	-13.02%	SMA50	-7.28%	SMA200	-16.80%	Trades		Volume	283,463	Change	-0.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60

Show Previous Ratings

Dec-24-24 08:20AM	Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial (Clinical Trials Arena)
Dec-23-24 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Business Wire)
Dec-19-24 04:59PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 07:30AM	Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases (Business Wire)
Dec-04-24 07:40AM	Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment (Clinical Trials Arena) -11.35%
07:30AM	Loading…
Dec-03-24 07:30AM	Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity (Business Wire)
Dec-02-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences (Business Wire)
Nov-30-24 06:00AM	Arrowhead price target lowered to $24 from $27 at Bernstein (TipRanks)
Nov-29-24 01:00AM	Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance (TipRanks)
Nov-28-24 08:15AM	Sarepta price target lowered to $202 from $205 at Needham (TipRanks)
Nov-27-24 12:40PM	Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +24.23%
11:07AM	Arrowhead Stock Rockets 16% After Major Licensing Deal (GuruFocus.com)
07:21AM	Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments (TipRanks)
07:20AM	Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board (TipRanks)
04:33AM	Arrowhead and Sarepta link for rare genetic disease treatments (Pharmaceutical Technology)
02:04AM	Loading…
02:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... (GuruFocus.com)
Nov-26-24 05:18PM	Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal (Investor's Business Daily) +12.03%
04:05PM	Arrowhead Pharma, Sarepta TX ink new gene therapy deal (Yahoo Finance Video)
04:00PM	Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results (Business Wire)
09:06AM	Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta (Investor's Business Daily)
07:00AM	Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs (Business Wire)
07:00AM	Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs (Business Wire)
Nov-22-24 07:41AM	Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-19-24 03:38AM	Arrowhead Pharmaceuticals submits plozasiran NDA to treat FCS (Pharmaceutical Business Review)
Nov-18-24 07:31AM	Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome (Business Wire)
07:30AM	Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran (Business Wire)
Nov-05-24 07:30AM	Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results (Business Wire)
Nov-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences (Business Wire)
Nov-01-24 07:30AM	Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, Well Get There Soon, to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome (Business Wire)
Oct-16-24 01:01PM	State Street Corp's Strategic Acquisition in Arrowhead Pharmaceuticals (GuruFocus.com) +6.14%
04:30PM	Loading…
Oct-14-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 05:53PM	Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Sep-24-24 06:53AM	Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand (Clinical Trials Arena)
Sep-23-24 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Business Wire)
Sep-11-24 06:12AM	FDA grants breakthrough therapy status to Arrowheads plozasiran (Pharmaceutical Technology)
Sep-10-24 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran (Business Wire)
Sep-03-24 10:36AM	Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug (Investopedia)
06:33AM	Arrowhead to file NDA after pivotal rare disease trial meets all endpoints (Clinical Trials Arena)
Sep-02-24 06:36AM	Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome (Business Wire)
Aug-21-24 07:30AM	Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome (Business Wire) +6.95%
Aug-16-24 06:00AM	Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance (BioPharma Dive)
Aug-15-24 10:52AM	Arrowhead announces push into obesity space with two gene therapies (Pharmaceutical Technology)
Aug-14-24 01:30PM	Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies (Business Wire)
Aug-08-24 04:37PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -9.44%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results (Business Wire)
04:00PM	Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street (Business Wire)
Jul-29-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-24-24 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results (Business Wire)
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-25-24 01:55PM	Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial (Business Wire)
Jun-24-24 07:30AM	Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE (Business Wire) +6.82%
Jun-03-24 03:55PM	Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? (Benzinga) +7.28%
07:30AM	Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome (Business Wire)
May-31-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences (Business Wire)
May-29-24 05:30AM	Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia (Business Wire)
May-28-24 06:04AM	Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia (Business Wire)
May-20-24 11:04AM	Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients (MT Newswires)
06:00AM	Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma (Business Wire)
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace)
May-10-24 01:03PM	Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations (GuruFocus.com) -10.68%
12:26PM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript (Insider Monkey)
11:32AM	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating (MT Newswires)
May-09-24 11:54PM	ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024 (InvestorPlace)
04:34PM	Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 (MT Newswires)
04:14PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results (Business Wire)
May-03-24 07:26AM	Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug (MT Newswires)
May-02-24 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
Apr-29-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences (Business Wire)
Apr-26-24 07:30AM	Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars (Business Wire)
Apr-24-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results (Business Wire) -6.10%
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease (Business Wire)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-07-24 09:00AM	Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo (Business Wire)
Apr-04-24 01:27AM	Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ... (GuruFocus.com)
Apr-01-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -7.26%
Mar-25-24 08:00AM	Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data (Business Wire)
Mar-11-24 06:53PM	The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 (InvestorPlace) -12.11%
Mar-08-24 11:29PM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares (GuruFocus.com)
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy (Business Wire)
Mar-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences (Business Wire)
Feb-07-24 10:42AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:02AM	Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-06-24 04:32PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:32PM	Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ... (GuruFocus.com)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results (Business Wire)
Jan-22-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results (Business Wire)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-09-24 03:02AM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 16,104 Shares (GuruFocus.com)
Jan-06-24 01:01PM	Arrowhead Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-05-24 05:00PM	Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million (Business Wire) +10.90%
11:02AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 9,952 Shares (GuruFocus.com)
Jan-03-24 07:00AM	Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock (Business Wire)
Dec-29-23 04:01PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-24-23 09:01AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares (GuruFocus.com)
Dec-21-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease (Business Wire)
Dec-20-23 07:30AM	Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.23%
Dec-01-23 09:32AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.29%
Nov-30-23 12:22PM	Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -26.85%
Nov-29-23 04:51PM	Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End Results (GuruFocus.com)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anzalone Christopher Richard	Chief Executive Officer	Dec 23 '24	Sale	19.59	12,563	246,109	3,775,772	Dec 23 04:39 PM
Anzalone Christopher Richard	Officer	Dec 23 '24	Proposed Sale	19.59	12,563	246,085		Dec 23 04:16 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 18 '24	Sale	21.24	26,712	567,486	3,688,335	Dec 20 06:04 PM
Waddill William D.	Director	Dec 17 '24	Sale	22.04	3,747	82,584	40,378	Dec 18 06:19 PM
Waddill William D.	Director	Dec 16 '24	Sale	21.90	3,748	82,081	44,125	Dec 18 06:19 PM
GIVEN DOUGLAS B	Director	Dec 16 '24	Sale	21.90	5,000	109,500	124,714	Dec 18 06:18 PM
GIVEN DOUGLAS B	Director	Dec 17 '24	Sale	22.04	547	12,056	124,167	Dec 18 06:18 PM
Vakiener Victoria	Director	Dec 16 '24	Sale	21.91	8,994	197,059	21,211	Dec 18 06:15 PM
Anzalone Christopher Richard	Officer	Dec 18 '24	Proposed Sale	21.24	26,712	567,415		Dec 18 04:41 PM
GIVEN DOUGLAS B	Director	Dec 17 '24	Proposed Sale	21.98	547	12,026		Dec 17 05:06 PM
Waddill William D.	Director	Dec 17 '24	Proposed Sale	22.03	3,747	82,552		Dec 17 04:53 PM
Waddill William D.	Director	Dec 16 '24	Proposed Sale	21.89	3,748	82,056		Dec 16 04:44 PM
Vakiener Victoria	Director	Dec 16 '24	Proposed Sale	21.91	8,994	197,066		Dec 16 04:30 PM
GIVEN DOUGLAS B	Director	Dec 16 '24	Proposed Sale	21.89	5,000	109,470		Dec 16 04:15 PM
Oliver Tracie	Chief Commercial Officer	Jul 02 '24	Sale	25.28	9,394	237,480	127,107	Jul 03 05:27 PM
Vakiener Victoria	Director	May 02 '24	Sale	23.31	1,799	41,935	30,205	May 06 06:04 PM
Hamilton James C	Chief Discovery/Trans Medicine	Apr 01 '24	Sale	28.03	6,000	168,180	204,851	Apr 03 06:05 PM
Lu Hongbo	Director	Mar 19 '24	Buy	28.00	1,000	28,000	32,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 20 '24	Buy	27.50	1,000	27,500	33,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 18 '24	Buy	27.49	1,000	27,490	31,680	Mar 20 07:06 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Mar 06 '24	Sale	35.19	40,000	1,407,600	400,600	Mar 08 05:54 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Option Exercise	14.54	57,499	836,035	3,772,547	Feb 02 05:25 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Sale	32.35	57,499	1,860,019	3,715,048	Feb 02 05:25 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 12 '24	Sale	36.89	7,940	292,904	210,851	Jan 17 06:32 PM
GIVEN DOUGLAS B	Director	Jan 11 '24	Sale	38.06	2,911	110,788	129,711	Jan 16 06:06 PM
Waddill William D.	Director	Jan 11 '24	Sale	38.07	3,934	149,759	47,870	Jan 16 06:06 PM
Ferrari Mauro	Director	Jan 11 '24	Sale	38.06	3,147	119,787	60,778	Jan 16 06:06 PM
Vakiener Victoria	Director	Jan 11 '24	Sale	38.10	4,720	179,813	32,001	Jan 16 06:06 PM
Oliver Tracie	Chief Commercial Officer	Jan 05 '24	Sale	33.89	74	2,508	136,501	Jan 08 05:17 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 05 '24	Sale	35.27	16,104	567,910	440,600	Jan 08 05:16 PM
San Martin Javier	Chief Medical Officer	Jan 05 '24	Sale	35.26	8,303	292,804	198,497	Jan 08 05:16 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 05 '24	Sale	35.18	32,143	1,130,748	218,791	Jan 05 08:02 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 03 '24	Sale	32.19	6,300	202,781	175,934	Jan 05 08:02 PM
O'Brien Patrick	COO and General Counsel	Jan 05 '24	Sale	35.27	22,841	805,716	464,385	Jan 05 07:58 PM
O'Brien Patrick	COO and General Counsel	Jan 03 '24	Sale	32.28	8,749	282,439	403,826	Jan 05 07:58 PM
O'Brien Patrick	COO and General Counsel	Jan 04 '24	Sale	32.63	1,600	52,208	402,226	Jan 05 07:58 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '24	Sale	31.01	9,952	308,637	3,715,048	Jan 04 05:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARWR

Arrowhead Pharmaceuticals Inc

Upgrade your FINVIZ experience